FDA Approves First Drug to Treat Group of Rare Blood Disorders in Nearly 14 Years
Approval is for hypereosinophilic syndrome, which occurs when there is a high number of a type of white blood cells The U.S. Food and Drug Administration approved Nucala (mepolizumab) for ad…
